Are biological targets the final goal for rheumatoid arthritis therapy?

Bibliography

• Caporali R, Caprioli M, Pallavicini FB, DMARDs and infections in rheumatoid arthritis. Autoimmun Rev 2008;8:139-43
   PubMed Web of Science ®Google Scholar
• Curtis JR, Patkar N, Xie A, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33
   PubMed Web of Science ®Google Scholar
• Rai P, Mallidi S, Zheng X, Development and applications of photo – triggered theranostic agents. Adv Drug Deliv Rev 2010;52:1094-124
   Google Scholar
• Hogset A, Prasmickaite L, Selbo PK, Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004;56:95-115
   PubMed Web of Science ®Google Scholar
• Hou WS, Li Z, Buttner FH, Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol Chem 2003;384:891-7
   PubMed Web of Science ®Google Scholar
• Desai N, Yang SA, Dykes D, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• Amrutkar RD. DMARD'S and biological agents: the second line treatment for rheumatoid arthritis. IJPRD 2010;2:138-46
   Google Scholar
• Kooloos WM, Jong D, Huizinga TWJ, Potential role of pharmacogenetics in anti – TNF treatment of rheumatoid arthritis and crohn's disease. Drug Discov Today 2007;12:125-31
   PubMed Web of Science ®Google Scholar
• Scott D L. Smith CK.What are the consequences of early rheumatoid arthritis for the individual? J Clin Rheumatol 2005;19:117-36
   Web of Science ®Google Scholar
• Chen CJ, Lai HM. Biologics in the treatment of rheumatoid arthritis: recent advances. Fofmosan J Rheumatol 2008;22:12-24
   Google Scholar
• Taylor PC, Mehta P, Tull T. An etiopathology of rheumatoid arthritis. Rheumatoid Arthritis 2009;38:164-9
   Google Scholar
• Mody GM, Hammond MG, Naidoo PD. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Cl Rh 2008;22:621-41
   PubMed Web of Science ®Google Scholar
• Yocum DET. Cells: pathogenic Cells and Therapeutics in Rheumatoid Arthritis. Semin Arthritis Rheum 1999;29:27-35
   PubMed Web of Science ®Google Scholar
• Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Cl Rh 2007;21:27-42
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Fleischmann RM, Fox RI, A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
   PubMed Web of Science ®Google Scholar
• Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the ‘side effects' or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 2004;22:2-11
   Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;35:903-11
   Google Scholar
• Manghani M, Tymms K, Barrett C. Recommendations for the use of biologic agents for the treatment of rheumatic diseases. ARA Oral abstracts published in Internal Journal Medicine 2011;41:1-12
   Google Scholar
• Kavanaugh A, Lee SJ. Adverse reactions to biologic agents: focus on autoimmune disease therapies. Best Pract Res Cl Rh 2005;116:900-5
   Google Scholar
• Khraishi M, Russell A, Olszynski WP, Safety profile of abatacept in Rheumatoid Arthritis: a Review. Clin Ther 2010;32:1855-70
   PubMed Web of Science ®Google Scholar
• Tang B, Rahman M, Waters HC, Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
   PubMed Web of Science ®Google Scholar
• Broeder AA, Jong E, Franssen MJA, Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Varin S, Cormier G, 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine 2007;74:144-7
   PubMed Web of Science ®Google Scholar
• Atzeni F, Doria A, Maurizio T, Puttini PS. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun Rev 2007;6:553-8
   PubMed Web of Science ®Google Scholar
• Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32
   PubMed Web of Science ®Google Scholar
• Romas E, Sims NA, Hards DK, Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen induced arthritis. Am J Pathol 2002;161:1419-27
   PubMed Web of Science ®Google Scholar
• Rheumatology therapeutics: drugs and biologics. FDA public health advisory, Washington, DC: FDA/Center for Drug Evaluation and Research, 2010. Available from http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm105782.htm [Last] [accessed 9 january 2010]
   Google Scholar
• Rosenblum H, Amital H. Anti – TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011;10:563-8
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Lee SJ. Adverse reactions to biologic agents: focus on autoimmune disease therapies. Best Pract Res Cl Rh 2005;116:900-5
   Google Scholar
• Maini RN, Breedveld F, Furst D, Infliximab (chimeric antitumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9
   PubMed Web of Science ®Google Scholar
• Feldman M, Maini RN. Anti-TNFalpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 2001;19:163-96
   PubMed Web of Science ®Google Scholar
• Adalimumab product information – Licensing action 12/31/2012. DC: FDA/Center for Drug Evaluation and Research, 2009. Available from: http://www.fda.gov/ Drugs /DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm [Last accessed 29 October 2009]
   Google Scholar
• Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Cl Rh 2003;17:345-63
   PubMed Web of Science ®Google Scholar
• Boyce EG, Halilovic J, Oby SU. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Therap 2010;32:2010
   Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
   PubMed Web of Science ®Google Scholar
• Valesini G, Iannuccelli C, Marocchi E, Biological and clinical effects of anti – TNF a treatment. Autoimmun Rev 2007;7:35-41
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Future treatment. Bailliere Clin Rheumatol 1997;11:83-97
   PubMedGoogle Scholar
• Simon MB, Swift B. What next for rheumatoid arthritis therapy? Current Opinion in Pharmacology. Curr Opin Pharmacol 2004;4:276-80
   PubMed Web of Science ®Google Scholar
• Wong M, Ziring D, Kim S, TNFalpha blockade in human diseases: Mechanism and future directions. Clin Immunol 2008;126:121-36
   PubMed Web of Science ®Google Scholar
• Wada M, Kawahito Y, Kimura S, siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis. Biochem Biophys Res Commun 2009;11:353-9
   Google Scholar
• Muller-Ladner U, Kriegsmann J, Franklin BN, Synovial fibroblasts of patients with rheumatoid arthritis attaches to and invades normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-15
   PubMed Web of Science ®Google Scholar
• Tarner IH, Lander UM, Fathman CG. Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun Rev 2006;5:148-52
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83
   PubMed Web of Science ®Google Scholar
• Wunder A, Ladner MU, Stelzer EH, Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003;9:4793-801
   Google Scholar
• Peters T. Serum albumin. Adv Protein Chem 1985;3:161-245
   Google Scholar
• Fasano M, Curry S, Terreno E, The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005;57:787-96
   PubMed Web of Science ®Google Scholar
• Carter DC, Twigg PD, Miller T Y. Three-dimensional structure of human serum albumin. Science 1989;244:1195-8
   PubMed Web of Science ®Google Scholar
• Yang A, Tao C, De T, Increased antitumor activity,intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• Elsadek B, Kratz F. Impact of albumin on drug delivery — New applications on the horizon. J Controlled Release 2012;157:4-28
   PubMed Web of Science ®Google Scholar
• Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed-Nanotechnol 2005;1:193-212
   PubMed Web of Science ®Google Scholar
• Yuan F, Quan LD, Cui L, Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev 2012;1:1-15
   Google Scholar
• Elsadek B, Kratz F. Impact of albumin on drug delivery – New applications on the horizon. J Control Release 2012;157:4-28
   PubMed Web of Science ®Google Scholar
• Delgado M, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-B and IFN regulatory factor 1 activation. J Immunol 1999;162:4685-96
   PubMed Web of Science ®Google Scholar
• Delgado M, Abad C, Leceta J, Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001;7:563-8
   PubMed Web of Science ®Google Scholar
• Juarranz Y, Abad C, Martinez C, Protective effect of vasoactive intestinal peptide on bone destruction in the collagen – induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005;7:1034-44
   Google Scholar
• Rey EG, Delgado M. Vasoactive intestinal peptide inhibits cycloxygenase – 2 expression in activated macrophages, microglia, and dendritic cells. Brain Behav Immun 2008;22:35-41
   PubMed Web of Science ®Google Scholar
• Kim KS, Park SJ, Yang JA, Injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis. Acta Biomater 2011;7:666-74
   PubMed Web of Science ®Google Scholar
• Zhao X, Alexander C, Fraser J. Intrarticular delivery: A fast growing approach. US20077226972; 2007
   Google Scholar
• Callegaro L, Renier D. Sulphated hyaluronic acid for treating osteoarthiritis. US20090197807; 2010
   Google Scholar
• Betre H, Liu W, Zalutsky MR, A thermally responsive biopolymer for intra-articular drug delivery. J Controlled Release 2006;115:175-82
   PubMed Web of Science ®Google Scholar
• Tomlinson E. Theory and practice of site – specific drug delivery. Adv Drug Deliv Rev 1987;1:87-198
   Google Scholar
• Hoshi K, Mizushima Y, Shiokawa Y, Double – blind study with liposteroid in rheumatoid arthritis. Drugs Exp Clin Res 1985;11:621-6
   PubMedGoogle Scholar
• Richards P J, Williams B D, Williams A S. Suppression of chronic streptococcal cell wall – induced arthritis in lewis rats by liposomal clodronate. Rheumatology 2001;40:978-87
   PubMed Web of Science ®Google Scholar
• Chandrasekar D, Sistla R, Ahmad FJ, The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 2007;28:504-12
   PubMed Web of Science ®Google Scholar
• Turk MJ, Breur GJ, Widmer WR, Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 2002;46:1947-55
   PubMed Web of Science ®Google Scholar
• Paulos C M, Turk M J, Breur G J, Folate receptor – mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliver Rev 2004;56:1205-17
   PubMed Web of Science ®Google Scholar
• Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage And repair. Cell Death Differ 2007;14:1315-23
   PubMed Web of Science ®Google Scholar
• Varani K, Padovan M, Govoni M, The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev 2010;10:61-4
   PubMed Web of Science ®Google Scholar
• Ochaion A, Yehuda SB, Cohen S, The A3 adenosine receptor agonist CF502 inhibits the PI3K,PKB/Akt and NF-kB signalling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochem Pharmacol 2008;76:482-94
   PubMed Web of Science ®Google Scholar
• Morovic-Vergles J, Culo MI, Gamulin S, Culo F. Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheum Int 2008;29:167-71
   PubMed Web of Science ®Google Scholar
• Dodds RA, Drake FH, Holmes S, Human osteoclasts cathepsin K is processed intracellularly prior to attachment and bone resorption.J Bone Miner. 2001;16:478-86
   Google Scholar
• Hou WS, Li W, Keyszer G, Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 2002;46:663-74
   PubMed Web of Science ®Google Scholar
• Skoumal M, Haberhauer G, Kolarz G, Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 2004;7:65-70
   Google Scholar
• Yasuda Y, Kaleta J, Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv 2005;57:973-93
   PubMed Web of Science ®Google Scholar
• Hayami T, Zhuo Y, Welsolowski GA, Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012;50:1250-9
   PubMed Web of Science ®Google Scholar
• Liu C. Progranulin: A promising therapeutic target for rheumatoid arthritis. FEBS Lett 2011;585(23):3675-80
   PubMed Web of Science ®Google Scholar
• Tang W, Lu Y, Tian Q-Y, The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011;332:478-84
   PubMed Web of Science ®Google Scholar
• Adigbi D K, MacRobert A J. Photochemical internalisation: the journey from basic scientific concept to the threshold of clinical application. Curr Opin Pharmacol 2012;12:1-5
   PubMedGoogle Scholar
• Nyman ES, Hynninen PH. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol 2004;73:1-28
   Web of Science ®Google Scholar
• Schutz C, Schmitt F, Lagopoulos L, Efficient delivery of photosensitizers for rheumatoid arthritis(RA) treatment by photodynamic therapy (PDT). Eur Cell Mater 2008;16:53
   Google Scholar
• Gabriel D, Busso N, Lange N, Thrombinsensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. J Control Release 2009;138:225-34
   PubMed Web of Science ®Google Scholar
• Liu TWB, Chen J, Burgess L, Multimodal bacteriochlorophyll theranostic agent. Thno 2011;1:354-62
   Google Scholar